These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 3714570)

  • 1. [Platelet aggregation in patients with hyperlipoproteinemia treated with bezafibrate].
    Borowska A; Bachórzewska-Gajewska H; Kaliciński A
    Pol Tyg Lek; 1986 Mar; 41(9):273-6. PubMed ID: 3714570
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of the combined administration of guar-bezafibrate on lipid, apolipoprotein and lipoprotein in patients with primary hyperlipoproteinemia type II].
    Wirth A; Schlierf G; Middelhoff G; Arntz HR; Hansen W; Vollmar J; Bräuning C
    Beitr Infusionther Klin Ernahr; 1983; 12():99-108. PubMed ID: 6316922
    [No Abstract]   [Full Text] [Related]  

  • 3. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M
    Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effectiveness of bezafibrate in ambulatory treatment of hyperlipidemia].
    Bartnikowska E; Michajlik A; Wegrzyn B
    Pol Tyg Lek; 1983 Sep; 38(39):1219-21. PubMed ID: 6371736
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
    Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Behavior of serum lipids, blood coagulation factors, platelet aggregation, complement and serum immunoglobulins in a group of arteriosclerotic, hyperlipemic subjects treated with 3GS].
    D'Eredità F; Avellone G; Novo S; Davì G; Abruzzese G; Di Liberti M; Pinto A; Riolo F
    Clin Ter; 1981 Feb; 96(3):303-24. PubMed ID: 7307448
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term effects of bezafibrate and of a bezafibrate and cholestyramine combination on lipids and lipoprotein lipids in type IIa hypercholesterolaemic patients.
    Sommariva D; Tirrito M; Bonfiglioli D; Pogliaghi I; Branchi A; Cabrini E
    Int J Clin Pharmacol Res; 1986; 6(3):249-53. PubMed ID: 3744628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients.
    Waysbort J; Schwartz S; Brunner D
    Arzneimittelforschung; 1994 Nov; 44(11):1217-22. PubMed ID: 7893284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IIB and IV].
    Chwistecki K; Mrukowicz M; Kopel E
    Przegl Lek; 1984; 41(9):581-6. PubMed ID: 6393227
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of bezafibrate on disorders of lipid metabolism].
    Stryjek-Kamińska D; Ilińska-Debniak K; Bartosiewicz W; Szczepanik Z
    Pol Tyg Lek; 1983 Dec; 38(50):1567-71. PubMed ID: 6379618
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients.
    Arruzazabala ML; Más R; Molina V; Carbajal D; Mendoza S; Fernández L; Valdés S
    Int J Tissue React; 1998; 20(4):119-24. PubMed ID: 10093795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia.
    Hailer S; Pogarell O; Keller C; Wolfram G
    Arzneimittelforschung; 1996 Sep; 46(9):879-83. PubMed ID: 8876936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
    Branchi A; Rovellini A; Sommariva D; Gugliandolo AG; Fasoli A
    Thromb Haemost; 1993 Aug; 70(2):241-3. PubMed ID: 8236126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
    Kokot F; Szczechowska E
    Z Gesamte Inn Med; 1981 Jul; 36(13):454-7. PubMed ID: 7025475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased plasma fibrinogen and platelet-aggregates in type II hyperlipoproteinaemia.
    Lowe GD; Drummond MM; Third JL; Bremner WF; Forbes CD; Prentice CR; Lawrie TD
    Thromb Haemost; 1980 Feb; 42(5):1503-7. PubMed ID: 7368154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients.
    Strano A; Davì G; Averna M; Rini GB; Novo S; Di Fede G; Mattina A; Notarbartolo A
    Thromb Haemost; 1982 Aug; 48(1):18-20. PubMed ID: 6753232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Results of linseed oil and olive oil therapy in hyperlipoproteinemia patients].
    Fischer S; Honigmann G; Hora C; Schimke E; Beitz J; Hanefeld M; Leonhardt W; Haller H; Förster W; Schliack V
    Dtsch Z Verdau Stoffwechselkr; 1984; 44(5):245-51. PubMed ID: 6391903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.